Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase

This publication has 13 references indexed in Scilit:

• Activation of Nonreceptor Tyrosine Kinase Bmx/Etk Mediated by Phosphoinositide 3-Kinase, Epidermal Growth Factor Receptor, and ErbB3 in Prostate Cancer Cells
  Journal of Biological Chemistry, 2007
• An efficient rapid system for profiling the cellular activities of molecular libraries
  Proceedings of the National Academy of Sciences, 2006
• 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2
  Journal of Medicinal Chemistry, 2005
• Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer
  Journal of Clinical Oncology, 2005
• Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
  Science, 2005
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
  Proceedings of the National Academy of Sciences, 2005
• Etk/Bmx as a Tumor Necrosis Factor Receptor Type 2-Specific Kinase: Role in Endothelial Cell Migration and Angiogenesis
  Molecular and Cellular Biology, 2002
• Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
  Proceedings of the National Academy of Sciences, 1998
• Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells
  Proceedings of the National Academy of Sciences, 1998
• Antisense oligodeoxynucleotides to the blk tyrosine kinase prevent anti-mu-chain-mediated growth inhibition and apoptosis in a B-cell lymphoma.
  Proceedings of the National Academy of Sciences, 1993